19-Apr-2024
No headlines found.
Blueprint Medicines to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024
PRNewswire (Thu, 18-Apr 8:00 AM ET)
PRNewswire (Thu, 11-Apr 8:00 AM ET)
Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PRNewswire (Sat, 6-Apr 1:03 AM ET)
PRNewswire (Fri, 23-Feb 8:00 AM ET)
Blueprint Medicines Reports Fourth Quarter and Full Year 2023 Results
PRNewswire (Thu, 15-Feb 7:00 AM ET)
PRNewswire (Thu, 1-Feb 8:00 AM ET)
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.
Blueprint Medicines trades on the NASDAQ stock market under the symbol BPMC.
As of April 19, 2024, BPMC stock price declined to $86.85 with 773,858 million shares trading.
BPMC has a beta of 1.07, meaning it tends to be more sensitive to market movements. BPMC has a correlation of 0.06 to the broad based SPY ETF.
BPMC has a market cap of $5.32 billion. This is considered a Mid Cap stock.
Last quarter Blueprint Medicines reported $72 million in Revenue and -$1.82 earnings per share. This beat revenue expectation by $5 million and exceeded earnings estimates by $.22.
In the last 3 years, BPMC stock traded as high as $117.86 and as low as $37.82.
The top ETF exchange traded funds that BPMC belongs to (by Net Assets): VTI, VB, IWM, VXF, VBK.
BPMC has outperformed the market in the last year with a return of +77.4%, while the SPY ETF gained +21.2%. In the last 3 month period, BPMC beat the market returning +9.0%, while SPY returned +4.3%. However, in the most recent 2 weeks BPMC has underperformed the stock market by returning -4.2%, while SPY returned -3.5%.
BPMC support price is $85.98 and resistance is $91.82 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BPMC stock will trade within this expected range on the day.